| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/15/2011 | EP2331131A1 Treating cancer by modulating rna helicases |
| 06/15/2011 | EP2331130A2 Ige antibodies for the treatment of cancer |
| 06/15/2011 | EP2331129A1 Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| 06/15/2011 | EP2331128A1 Composition comprising chitosan for ocular administration of vaccine(s) to avians |
| 06/15/2011 | EP2331127A2 Vaccine adjuvant combinations |
| 06/15/2011 | EP2331126A1 Immunological composition |
| 06/15/2011 | EP2331125A1 Immunotherapy for chronic hepatitis c virus infection |
| 06/15/2011 | EP2331124A1 T-cell antigen peptide from allergen for stimulation of il-10 production |
| 06/15/2011 | EP2331123A2 Compositions and methods for the treatment of hepatitis c |
| 06/15/2011 | EP2331122A2 A vaccine for porcine post-weaning diarrhea caused by enterotoxigenic escherichia coli |
| 06/15/2011 | EP2331121A1 Vaccine comprising protein nmbo964 from meisseria meningitidis |
| 06/15/2011 | EP2331120A1 Factor h binding protein immunogens |
| 06/15/2011 | EP2331119A1 Malaria vaccine |
| 06/15/2011 | EP2331118A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| 06/15/2011 | EP2331117A1 Vaccines containing canine parvovirus genetic variants |
| 06/15/2011 | EP2331115A2 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 06/15/2011 | EP2331104A2 Method of inducing an anti-viral immune response |
| 06/15/2011 | EP2331090A1 Stable liquid antibody formulation |
| 06/15/2011 | EP2331078A1 Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| 06/15/2011 | EP2142570B1 Anti-epcam antibody and uses thereof |
| 06/15/2011 | EP1766093B1 Antibodies against clostridium difficile toxins and uses thereof |
| 06/15/2011 | EP1740217B1 Meningococcal conjugate vaccination |
| 06/15/2011 | EP1706140B1 Methods for tailoring the immune response to an antigen or immunogen |
| 06/15/2011 | EP1699480B1 Allogeneic tumor therapeutic agent |
| 06/15/2011 | EP1651765B1 Novel photobacterium damselae nucleotide and amino acid sequences and uses thereof |
| 06/15/2011 | EP1500665B1 METHODS FOR CONSTRUCTING scDb LIBRARIES |
| 06/15/2011 | EP1417229B1 Methods and compounds for the targeting of protein to exosomes |
| 06/15/2011 | EP0939804B2 NEUTROKINE alpha |
| 06/15/2011 | CN201861992U Multiple coating mirco-capsulation lactic acid bacteria (MCM-LAB) structure |
| 06/15/2011 | CN1942578B Low virulent strain of recombinant newcastle disease lasota vaccine expressing HA protein of avian influenza-H5 virus |
| 06/15/2011 | CN1849135B Methods for treating interleukin-6-related diseases |
| 06/15/2011 | CN1820734B Treatment with anti-erbb2 antibodies |
| 06/15/2011 | CN1780907B Anti-CCR5 antibody |
| 06/15/2011 | CN1680432B Viral protein |
| 06/15/2011 | CN1452636B Human monoclonal antibodies to dendritis cells |
| 06/15/2011 | CN102099468A Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| 06/15/2011 | CN102099378A Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same |
| 06/15/2011 | CN102099377A CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 06/15/2011 | CN102099372A Anti-amyloid immunogenic compositions, methods and uses |
| 06/15/2011 | CN102099055A B7 family member zb7h6 and related compositions and methods |
| 06/15/2011 | CN102099054A Respiratory syncytial virus renders dendritic cells tolerogenic |
| 06/15/2011 | CN102099053A Combined measles-human papilloma vaccine |
| 06/15/2011 | CN102099052A 疫苗 Vaccine |
| 06/15/2011 | CN102093479A Recombinant chimeric antibody of anti-human vascular endothelium growth factor receptor 2 |
| 06/15/2011 | CN102093477A Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| 06/15/2011 | CN102091329A Preparation method of inactivated porcine parvovirus vaccine and product thereof |
| 06/15/2011 | CN102091328A Staphylococcus hyicus inactivated vaccines, preparation method thereof and application thereof |
| 06/15/2011 | CN102091327A Preparation method of dendritic cell (DC) vaccine loaded with autologous tumor associated holoantigen |
| 06/15/2011 | CN101586120B Rabies virus Flury-LEP vaccine strain reverse genetic operating system and LEP green fluorescent protein recombination viral vector |
| 06/15/2011 | CN101496898B Vaccine for preventing and/or treating Helicobacter pylori infection |
| 06/15/2011 | CN101235086B Recombination human rabies viruses resisting antibody |
| 06/15/2011 | CN101182516B Bacterium surface displaying novel system, method and applications |
| 06/15/2011 | CA2725435A1 Vaccines for inclusion body hepatitis |
| 06/14/2011 | US7960535 Recombinant lipidated PsaA protein, methods of preparation and use |
| 06/14/2011 | US7960533 Nucleic acids coding for adhesion factor of group B Streptococcus, adhesion factors of group B Streptococcus and further uses thereof |
| 06/14/2011 | US7960527 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
| 06/14/2011 | US7960517 Methods for antibody engineering |
| 06/14/2011 | US7960516 Solid forms of anti-EGFR antibodies |
| 06/14/2011 | US7960515 Binding molecules to the human OX40 receptor |
| 06/14/2011 | US7960507 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| 06/14/2011 | US7960362 Synthetic agonists of TLR9 |
| 06/14/2011 | US7960361 Formulating an anti-cancer vaccine comprising an agent that can stimulate an immune response against IL-13R alpha 2 outside of the subject, and administering the vaccine to the subject |
| 06/14/2011 | US7960356 Induces production of a cytokine or activates dendritic cells, natural killer cells and monocytes; autoimmune disorders; vaccine |
| 06/14/2011 | US7960174 Hybridoma producing antibodies to Lawsonia intracellularis |
| 06/14/2011 | US7959934 Method for rapid generation of mature dendritic cells |
| 06/14/2011 | US7959932 Human rotavirus and vaccine composition comprising same |
| 06/14/2011 | US7959931 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants |
| 06/14/2011 | US7959930 Rescue of influenza virus |
| 06/14/2011 | US7959929 isolated influenza virus that is capable of infecting a canid animal; genetic engineered influenza virus; vaccines for inducing an immune response against an influenza virus; veterinary medicine |
| 06/14/2011 | US7959928 Viral like particle for use in for enhancing immune response and treating inflammatory and autoimmune disease |
| 06/14/2011 | US7959927 Mycoplasma hyopneumoniae bacterin vaccine |
| 06/14/2011 | US7959926 Using hydrophobic interaction chromatography (HIC) matrix to recover somatotropins |
| 06/14/2011 | US7959925 Trimeric OX40-immunoglobulin fusion protein and methods of use |
| 06/14/2011 | US7959924 Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof |
| 06/14/2011 | US7959923 Method for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA |
| 06/14/2011 | US7959922 Liquid anti-rabies antibody formulations |
| 06/14/2011 | US7959921 TNFα-neutralizing antibodies |
| 06/14/2011 | US7959920 Methods of making and using antibodies directed to parathyroid hormone |
| 06/14/2011 | US7959919 Administering antibody, peptides, oligonucleotides, peptitomimetics, or small organic molecules having a binding region specific to factor B; antiinflammatory agent treating rheumatoid arthritis, anaphylactic shock, myasthenia gravis, asthma, Alzheimer's disease, cardiopulmonary bypass inflammation |
| 06/14/2011 | US7959918 Methods for treating vascular disease |
| 06/14/2011 | US7959917 Binding members for IgE molecules |
| 06/14/2011 | US7959916 Negative immunomodulation of immune responses by ERp5 |
| 06/14/2011 | US7959915 Inhibitors of extracellular Hsp90 |
| 06/14/2011 | US7959911 Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids |
| 06/14/2011 | CA2517147C Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
| 06/14/2011 | CA2494962C Tyrosine kinase inhibitors |
| 06/14/2011 | CA2494241C Botulinum toxin pharmaceutical compositions |
| 06/14/2011 | CA2475534C Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 06/14/2011 | CA2458267C Bifunctional chelating agent for actinium |
| 06/14/2011 | CA2446260C Novel expression vectors and uses thereof |
| 06/14/2011 | CA2426292C Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 06/14/2011 | CA2413546C Modification of hepatitis b core antigen |
| 06/14/2011 | CA2405084C Neutralizing immunogenic hev polypeptides |
| 06/14/2011 | CA2399846C Gm-negative ehv-mutants |
| 06/14/2011 | CA2382331C Vaccine against intra-cellular pathogens |
| 06/14/2011 | CA2369622C Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| 06/14/2011 | CA2365416C Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 06/14/2011 | CA2338419C Pulmonary delivery of active agents |
| 06/14/2011 | CA2327389C Dna vaccine for horses containing as at least one adjuvant, polymers of acrylic or methacrylic acid, or copolymers of maleic anhydride and ethylene |
| 06/14/2011 | CA2324853C Monoclonal and chimeric antibodies specific for human tumor necrosis factor |